Literature DB >> 33354556

Cancerous Patient with COVID-19: Note on Data from the first 3-Month Period of Disease.

Beuy Joob1, Viroj Wiwanitkit2.   

Abstract

Entities:  

Year:  2020        PMID: 33354556      PMCID: PMC7745750          DOI: 10.1055/s-0040-1721214

Source DB:  PubMed          Journal:  South Asian J Cancer        ISSN: 2278-330X


× No keyword cloud information.
Coronavirus disease 2019 (COVID-19) is an important pandemic. From its origin in Republic of China, 1 this disease already affects more than 200 countries around the world. The infection can occur in any sex and age group. Malignancy is a possible comorbidity of COVID-19. There are few reported cases of COVID-19 in clinical oncology. 2 Here, the authors would like to share public data reported by local Center for Disease Control and Prevention of the second country where this disease occurred since January 2020. 3 During the 3-month period (January 2020–March 2020), there were 1,651 cases of COVID-19 with 10 deaths. There is a patient with underlying cancer, giving the incidence rate equal to 0.06%. This indexed case is a 48-year-old male patient who works as a singer in a local food shop. He is a known case of colon cancer who had just received surgery and chemotherapy for a few months (the complete chemotherapy was 3 months before). The patient died from respiratory failure on day 5 of hospitalization for antiviral therapy and isolated respiratory care. This is the first data of cancerous patient with COVID-19 from Indochina, an area with a heavy outbreak of COVID-19. According to the reports from Republic of China, malignancy might be associated with poor outcome in COVID-19. 4 Nevertheless, no conclusion should be presently drawn in out setting since it is only one event. It might only imply possibility for poor outcome in case with underlying malignancy.

Declaration of Patient Consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published, and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
  2 in total

Review 1.  [Diagnostic and therapeutic strategies of lung cancer patients during the outbreak of 2019 novel coronavirus disease (COVID-19)].

Authors:  L Yang; H Y Xu; Y Wang
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2020-04-23

2.  Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China.

Authors:  Zhongliang Wang; Bohan Yang; Qianwen Li; Lu Wen; Ruiguang Zhang
Journal:  Clin Infect Dis       Date:  2020-07-28       Impact factor: 9.079

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.